CYP3A5 gene polymorphisms and their impact on dosage and trough concentration of tacrolimus among kidney transplant patients: a systematic review and meta-analysis

2020 ◽  
Vol 20 (4) ◽  
pp. 553-562 ◽  
Author(s):  
Abdul Rafay Khan ◽  
Ali Raza ◽  
Sadaf Firasat ◽  
Aiysha Abid
2020 ◽  
Vol 8 (4) ◽  
pp. 47
Author(s):  
Api Chewcharat ◽  
Narut Prasitlumkum ◽  
Charat Thongprayoon ◽  
Tarun Bathini ◽  
Juan Medaura ◽  
...  

Background: The objective of this systematic review was to evaluate the efficacy and safety profiles of sodium-glucose co-transporter 2 (SGLT-2) inhibitors for treatment of diabetes mellitus (DM) among kidney transplant patients. Methods: We conducted electronic searches in Medline, Embase, Scopus, and Cochrane databases from inception through April 2020 to identify studies that investigated the efficacy and safety of SGLT-2 inhibitors in kidney transplant patients with DM. Study results were pooled and analyzed utilizing random-effects model. Results: Eight studies with 132 patients (baseline estimated glomerular filtration rate (eGFR) of 64.5 ± 19.9 mL/min/1.73 m2) treated with SGLT-2 inhibitors were included in our meta-analysis. SGLT-2 inhibitors demonstrated significantly lower hemoglobin A1c (HbA1c) (WMD = −0.56% [95%CI: −0.97, −0.16]; p = 0.007) and body weight (WMD = −2.16 kg [95%CI: −3.08, −1.24]; p < 0.001) at end of study compared to baseline level. There were no significant changes in eGFR, serum creatinine, urine protein creatinine ratio, and blood pressure. By subgroup analysis, empagliflozin demonstrated a significant reduction in body mass index (BMI) and body weight. Canagliflozin revealed a significant decrease in HbA1C and systolic blood pressure. In terms of safety profiles, fourteen patients had urinary tract infection. Only one had genital mycosis, one had acute kidney injury, and one had cellulitis. There were no reported cases of euglycemic ketoacidosis or acute rejection during the treatment. Conclusion: Among kidney transplant patients with excellent kidney function, SGLT-2 inhibitors for treatment of DM are effective in lowering HbA1C, reducing body weight, and preserving kidney function without reporting of serious adverse events, including euglycemic ketoacidosis and acute rejection.


2019 ◽  
Vol 51 (8) ◽  
pp. 2710-2713 ◽  
Author(s):  
Seun Deuk Hwang ◽  
Jin Ho Lee ◽  
Jong Hyun Jhee ◽  
Yoon Ji Kim ◽  
Keun-Myoung Park ◽  
...  

2021 ◽  
Vol 69 (4) ◽  
pp. 547-560
Author(s):  
Merve Akyol ◽  
Enes Çevik ◽  
Duygu Ucku ◽  
Cem Tanrıöver ◽  
Barış Afşar ◽  
...  

2020 ◽  
Author(s):  
Panupong Hansrivijit ◽  
Tejaswi Kanderi ◽  
Max M. Puthenpura ◽  
Nasrollah Ghahramani ◽  
Charat Thongprayoon ◽  
...  

Author(s):  
Anahita Abbasi ◽  
Padideh Ebadi ◽  
Ramin Yaghobi ◽  
Mohammad Hossein Karimi

Acute organ rejection remains a serious clinical challenge. Novel accessible biomarkers of acute rejection could easily enable us to detect the rejection earlier and make more fine-tuned calibration of immunosuppressive or new target treatment possible. Control of gene expression by microRNAs influences many cellular functions, including cellular differentiation, cell proliferation, cell development, and functional regulation of the immune system. Therefore, this study was aimed to investigate if miRNA146a G>C and miRNA196a-2 C>T gene polymorphisms are associated with kidney transplant rejection in Iranian patients. Tissue samples were collected from 100 renal transplant patients between the years 2009 and 2013. The miRNA146a G>C (rs2910164) and miRNA196a-2 C>T (rs11614913) gene polymorphisms were evaluated in kidney transplant patients; using the in-house-polymerase chain Reaction-restriction fragment length polymorphism (PCR-RFLP) method. In this study, we found that the CC genotype, C and G alleles of the miRNA146a G>C polymorphism was associated with increased risk of transplant rejection in kidney transplant patients (p=0.003, p=0.01 and p=0.01), respectively. The CC genotype, T, and C alleles of the miRNA196a-2 C>T were also significantly more frequent in transplanted patients compared to healthy controls (p=0.02, p=0.05, and p=0.05), respectively. However, significant associations were not found between miRNA196a-2 C>T polymorphisms and kidney transplant rejection. The CC genotype, G, and C allele of the miRNA146a G>C and also, the CC genotype, T and C alleles of the miRNA196a-2 C>T may be genetically susceptible factors for transplant rejection and development of kidney disorders, especially in Iranian patients. Further studies are required to validate these findings in a larger population, as well as in patients with different ethnic origins.


2013 ◽  
Vol 26 (3) ◽  
pp. 201-206 ◽  
Author(s):  
Sara Hejr ◽  
Mohammad Hossein Karimi ◽  
Ramin Yaghobi ◽  
Eskandar Kamali-Sarvestani ◽  
Bita Geramizadeh ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document